Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 178
2007 247
2008 289
2009 313
2010 434
2011 385
2012 338
2013 297
2014 317
2015 363
2016 382
2017 368
2018 410
2019 431
2020 367
2021 323
2022 236
2023 314
2024 298
2025 330
2026 76

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,190 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.
Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL. Spicer JD, et al. J Thorac Oncol. 2024 Oct;19(10):1373-1414. doi: 10.1016/j.jtho.2024.06.010. Epub 2024 Jun 18. J Thorac Oncol. 2024. PMID: 38901648 Free article.
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
Spira AI, Paz-Ares L, Han JY, Shih JY, Mascaux C, Roy UB, Zugazagoitia J, Kim YJ, Chiu CH, Kim SW, Nadal E, Gil-Bazo I, Murphy SP, Anderson BG, Xia Y, Wang G, Bauml JM, Chioda M, Simoes J, Mahadevia PJ, Lopes G. Spira AI, et al. J Thorac Oncol. 2025 Jun;20(6):809-816. doi: 10.1016/j.jtho.2025.01.018. Epub 2025 Jan 24. J Thorac Oncol. 2025. PMID: 39864547 Free article. Clinical Trial.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Peters S, et al. J Thorac Oncol. 2025 Jan;20(1):76-93. doi: 10.1016/j.jtho.2024.09.1381. Epub 2024 Sep 5. J Thorac Oncol. 2025. PMID: 39243945 Free article. Clinical Trial.
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.
Mascaux C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, Bossé Y, Dammeijer F, Cavic M, Barr MP, Arulananda S, Armisen R, Berger AH, Bianchi F, Carbone DP, Cerciello F, Lockwood WW, Mitsudomi T, Ohara S, Politi K, Qin S, Roisman LC, Samstein R, Skoulidis F, Tan AC, Thomas A, Zhang J, Wynes MW, John T, Tsao MS; IASLC Basic and Translational Science Committee. Mascaux C, et al. J Thorac Oncol. 2025 Oct;20(10):1369-1391. doi: 10.1016/j.jtho.2025.05.024. Epub 2025 Jun 3. J Thorac Oncol. 2025. PMID: 40473107 Review.
50 Years of Progress in NSCLC: A New Fellow's Guide in the Clinic.
Naidoo J, Niroula A, Uprety D, Smeltzer M, Geissen N, Osarogiagbon RU, Mino-Kenudson M, Yatabe Y, Higgins K, Desai A, Reckamp KL, Lin JJ, Liu SV, Hegi-Johnson Franzcr F, Seetharamu N, Harpole D, Edelman MJ; IASLC Communications Committee. Naidoo J, et al. J Thorac Oncol. 2025 Oct;20(10):1392-1422. doi: 10.1016/j.jtho.2025.06.028. Epub 2025 Jul 3. J Thorac Oncol. 2025. PMID: 40617395 Review.
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
Kilickap S, Baramidze A, Sezer A, Özgüroğlu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang HG, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, Li Y, Zhu C, Kaul M, Perez J, Seebach F, Lowy I, Pouliot JF, Kim E, Magnan H. Kilickap S, et al. J Thorac Oncol. 2025 Jul;20(7):941-954. doi: 10.1016/j.jtho.2025.03.033. Epub 2025 Mar 19. J Thorac Oncol. 2025. PMID: 40118215 Free article. Clinical Trial.
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Bernabe Caro R, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, de Miguel MJ, Helissey C, Shu CA, Spira AI, Tomasini P, Yang JC, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Besse B, et al. J Thorac Oncol. 2025 May;20(5):651-664. doi: 10.1016/j.jtho.2024.12.029. Epub 2025 Jan 2. J Thorac Oncol. 2025. PMID: 39755170 Free article. Clinical Trial.
6,190 results